hotspot -WSS

hotspot

author：knowledge 2025-10-02 19:20:00 - browse：66533

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Intellia reports positive results for its CRISPR

leisure time

WSS

Thermo Fisher plant for manufacturing gene therapies to expand

Why are Kaiser Permanente staff considering a strike?

Experts study whether long Covid risk adds up with each reinfection

Experts study whether long Covid risk adds up with each reinfection

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

focus

hotspot

explore

Wildfire smoke exposes gaps in outdoor worker protections

It's been 20 years since Dolly the sheep. Where's my clone?

Cancer drug shortages should be causing more outrage

See how much Covid

In age of alternative facts, a scholarly course on calling out crap

Microbiome research is starting to find links to chronic diseases

State Dept. review finds Biden bears some blame for Afghanistan failures

EpiPen alternative approval delay highlights citizen petition issue

Affirmative action in medical school literally saved lives

Microbiome research is starting to find links to chronic diseases

hotspot

Cord blood banking comes at a high cost to babies

Senate HELP committee spars over health care workforce policies

Ukraine and a new approach to mental health in war

How Vertex's cystic fibrosis drug is changing patients' lives

Second xenotransplant done with gene

Readout LOUD podcast: possible new ALS drug, artificial wombs

leisure time

knowledge

hotspot

hotspot